The yellow fever vaccine-17D (YFV-17D) is one of the most successful vaccines ever developed, yet we understand little of the mechanisms by which it induces protective immunity. Research during the previous cycle has focused on understanding the immunological mechanisms by which YFV-17D stimulates broad and long lasting T and B cell responses. The results of this work can be summed up thus: (i) YFV-17D stimulates multiple Toll-like receptors (TLRs) on dendritic cells (DCs), and this leads to robust CD8+ T cell responses and a mixed Th1/Th2 profile. Furthermore, YFV-17D induces the mammalian target of ramayicn (mTOR) in plasmacytoid DCs, which mediates type I IFN production, and enhances the CD8+ T cell response, (ii) A systems biological analysis of humans vaccinated with YFV-17D, demonstrated a robust type I IFN genomic signature in most vaccinees. Importantly, a distinct signature which included eukaryotic translation initiation factor 2 alpha kinase 4 [EIF2AK4, a stress response gene, was capable of prediciting with 90% accuracy the magnitide of the CD8+ T cell responses, (iii) Analysis of an individual who developed serious adverse events shortly after YFV-17D vaccination, revealed robust T and B cell responses, but polymorphisms in the CCR5 and RANTES genes, and greatly enhanced numbers of inflamatory monocytes. Taken together, these observations provide new insights into the mode of action of YFV-17D. The present proposal will follow up these observations mechanistically, and determine whether such responses are unique to YFV-17D, relative to the wild type strain Asibi, and the related flavivirus dengue.
Aim 1 : To determine whether stimulation of the integrated stress response by YFV-17D is necessary for the induction of antigen-specific CD8+ T cell responses.
Aim 2 : To evaluate the innate and adaptive immune responses stimulated by YFV-17D versus Asibi Aim 3: To determine the role(s) played by inflammatory monocytes and CCR5 in the pathogenesis of yellow fever and dengue. The successful completion of these aims will offer new insights into the mode of action of YFV-17D

Public Health Relevance

The yellow fever vaccine-17D (YFV-17D) is one of the most successful vaccines ever made. The vaccine was developed empirically, thus despite its success we do not know the mechanisms by which it works. The present proposal will aim to discover mechanisms by which YFV-17D works, with a view to harnessing them in the design of future vaccines against global pandemics and emerging infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI057266-10
Application #
8468621
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
10
Fiscal Year
2013
Total Cost
$627,358
Indirect Cost
$129,916
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Fang, Fengqin; Yu, Mingcan; Cavanagh, Mary M et al. (2016) Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals. Cell Rep 14:1218-31
Ravindran, Rajesh; Loebbermann, Jens; Nakaya, Helder I et al. (2016) The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature 531:523-7
Chandele, Anmol; Sewatanon, Jaturong; Gunisetty, Sivaram et al. (2016) Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients from India. J Virol 90:11259-11278
Neu, Karlynn E; Henry Dunand, Carole J; Wilson, Patrick C (2016) Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol 42:48-55
DiLillo, David J; Palese, Peter; Wilson, Patrick C et al. (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605-10
Henry Dunand, Carole J; Leon, Paul E; Huang, Min et al. (2016) Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe 19:800-13
Qi, Qian; Cavanagh, Mary M; Le Saux, Sabine et al. (2016) Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med 8:332ra46
Ho, Irvin Y; Bunker, Jeffrey J; Erickson, Steven A et al. (2016) Refined protocol for generating monoclonal antibodies from single human and murine B cells. J Immunol Methods 438:67-70
Nakaya, Helder I; Clutterbuck, Elizabeth; Kazmin, Dmitri et al. (2016) Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc Natl Acad Sci U S A 113:1853-8
Burke, Rachel M; Suchdev, Parminder S; Rebolledo, Paulina A et al. (2016) Predictors of Inflammation in a Cohort of Bolivian Infants and Toddlers. Am J Trop Med Hyg 95:954-963

Showing the most recent 10 out of 202 publications